Synthesis of Carrier-Free Paclitaxel–Curcumin Nanoparticles: The Role of Curcuminoids

The systemic administration of paclitaxel (PTX)-based combinatorial therapies is significantly restricted due to the multidrug resistance. Curcumin (CUR) not only inhibits cancer-cell proliferation but also reverses the PTX resistance. However, achieving codelivery of these two drugs is a challenge...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaosmanoglu, Sena, Zhang, Yunsen, Zhou, Wenli, Ouyang, Defang, Chen, Xianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774928/
https://www.ncbi.nlm.nih.gov/pubmed/36551021
http://dx.doi.org/10.3390/bioengineering9120815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774928/
https://www.ncbi.nlm.nih.gov/pubmed/36551021
http://dx.doi.org/10.3390/bioengineering9120815

Ejemplares similares